Dr. Tolaney on Recent Advances in HR-Positive Breast Cancer

Sara M. Tolaney, MD, MPH
Published: Thursday, Sep 27, 2018



Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses recent advances in the treatment of patients with hormone receptor (HR)-positive breast cancer.

In the last few decades, there have been a lot of changes in the treatment landscape of HR-positive metastatic breast cancer, Tolaney says. Specifically, the introduction of mTOR inhibitors in the last decade, and the approval of 3 different CDK4/6 inhibitors in the last 3 years. The 3 FDA approved CDK4/6 inhibitors in this setting are abemaciclib (Verzenio), ribociclib (Kisqali), and palbociclib (Ibrance).

CDK4/6 inhibitors are being used in the upfront and second-line settings with fulvestrant. There are also data on the use of CDK4/6 inhibitors as monotherapy, such as abemaciclib in the refractory setting. Abemaciclib was approved by the FDA in February 2018 for use in combination with an aromatase inhibitor for the frontline treatment of postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer.


Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses recent advances in the treatment of patients with hormone receptor (HR)-positive breast cancer.

In the last few decades, there have been a lot of changes in the treatment landscape of HR-positive metastatic breast cancer, Tolaney says. Specifically, the introduction of mTOR inhibitors in the last decade, and the approval of 3 different CDK4/6 inhibitors in the last 3 years. The 3 FDA approved CDK4/6 inhibitors in this setting are abemaciclib (Verzenio), ribociclib (Kisqali), and palbociclib (Ibrance).

CDK4/6 inhibitors are being used in the upfront and second-line settings with fulvestrant. There are also data on the use of CDK4/6 inhibitors as monotherapy, such as abemaciclib in the refractory setting. Abemaciclib was approved by the FDA in February 2018 for use in combination with an aromatase inhibitor for the frontline treatment of postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x